Comparison of various studies' survival data in patients with mycosis fungoides and Sézary syndrome
| Study, first author, place, publication y . | Total patients studied, no. . | Inclusion of MF and/or SS . | Blood involvement, definition (N = no. patients) . | Median survival, y . | Independent prognostic variables identified . | |
|---|---|---|---|---|---|---|
| Blood involvement . | No blood involvement . | |||||
| Kim,15 California, 1995 | 106 | Erythrodermic MF and SS | Sézary cells > 5% of total lymphocytes (N = 35) | 2.6 | 6.8 | > 65 years, disease < 10 years, lymph node involvement stages N2, N3 |
| Diamandidou,21 Texas, 1999 | 115 | MF and SS | Sézary cells > 5% of total lymphocytes (N = 12) | 2.5 | 11.8 | age > 60 years, tumor stage T3, LDH > 10% above normal |
| Toro,25 New York, 1997 | 101 | MF and SS | > 20% lymphocytes with atypical nuclear convolutions (N = 8) | 1.25 | 15.8 | Skin stage, visceral involvement |
| Sausville,6 Maryland, 1988 | 152 | MF and SS | > 20% lymphocytes with atypical nuclear convolutions (N = 52) | 3.3 | 10 | Skin stage, visceral involvement |
| Schechter,10 Maryland, 1987 | 160 | MF and SS | Convoluted cells > 20% total lymphocytes (N = 60) | 3.5 | > 8 | Skin stage, age |
| Bernengo,30Italy, 1999 | 62 | SS | Sézary cells > 10% of peripheral blood leukocytes | 2.6 | — | Sézary cells > 15 μm, PAS + ve cytoplasmic inclusions, loss of CD7 antigen |
| Beuchner,31 Minnesota, 1983 | 39 | SS | > 1 × 109 cell per L | 3.3 | — | |
| Study, first author, place, publication y . | Total patients studied, no. . | Inclusion of MF and/or SS . | Blood involvement, definition (N = no. patients) . | Median survival, y . | Independent prognostic variables identified . | |
|---|---|---|---|---|---|---|
| Blood involvement . | No blood involvement . | |||||
| Kim,15 California, 1995 | 106 | Erythrodermic MF and SS | Sézary cells > 5% of total lymphocytes (N = 35) | 2.6 | 6.8 | > 65 years, disease < 10 years, lymph node involvement stages N2, N3 |
| Diamandidou,21 Texas, 1999 | 115 | MF and SS | Sézary cells > 5% of total lymphocytes (N = 12) | 2.5 | 11.8 | age > 60 years, tumor stage T3, LDH > 10% above normal |
| Toro,25 New York, 1997 | 101 | MF and SS | > 20% lymphocytes with atypical nuclear convolutions (N = 8) | 1.25 | 15.8 | Skin stage, visceral involvement |
| Sausville,6 Maryland, 1988 | 152 | MF and SS | > 20% lymphocytes with atypical nuclear convolutions (N = 52) | 3.3 | 10 | Skin stage, visceral involvement |
| Schechter,10 Maryland, 1987 | 160 | MF and SS | Convoluted cells > 20% total lymphocytes (N = 60) | 3.5 | > 8 | Skin stage, age |
| Bernengo,30Italy, 1999 | 62 | SS | Sézary cells > 10% of peripheral blood leukocytes | 2.6 | — | Sézary cells > 15 μm, PAS + ve cytoplasmic inclusions, loss of CD7 antigen |
| Beuchner,31 Minnesota, 1983 | 39 | SS | > 1 × 109 cell per L | 3.3 | — | |
Independent prognosis variables includes median survival of patients with blood involvement and patients without blood involvement in years from diagnosis and independent prognostic variables identified in the study.
SS indicates Sézary syndrome; MF mycosis fungoides.